A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.
증례보고
1/5 보강
[BACKGROUND] Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months.
APA
Chumbiauca E, Valdés Calero I, et al. (2026). A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.. Hormones (Athens, Greece), 25(1), 267-271. https://doi.org/10.1007/s42000-025-00738-z
MLA
Chumbiauca E, et al.. "A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.." Hormones (Athens, Greece), vol. 25, no. 1, 2026, pp. 267-271.
PMID
41288952 ↗
Abstract 한글 요약
[BACKGROUND] Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes.
[CASE PRESENTATION] We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.
[CONCLUSION] This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.
[CASE PRESENTATION] We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.
[CONCLUSION] This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.